Keiko Yamaguchi

Title: Keiko Yamaguchi: Innovator in Th1 Cell Detection

Introduction

Keiko Yamaguchi is a prominent inventor based in Kyoto, Japan. She has made significant contributions to the field of immunology, particularly in the detection of Th1 cells. With a total of four patents to her name, her work has the potential to impact the diagnosis and treatment of various diseases.

Latest Patents

Yamaguchi's latest patents focus on methods for detecting Th1 cells. The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functions as an adhesion molecule for activated lymphocytes. They identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that this ligand is selectively expressed in Th1 cells. Furthermore, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. The present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, as well as methods for screening inhibitors that suppress the adhesion of Th1 cells using the binding between CAR and CARL as an index. Additionally, the invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit this binding, and therapeutic compositions comprising these antibodies. These innovations are expected to be useful in diagnosing diseases, such as inflammation, where Th1 cell infiltration is involved, and in providing pharmaceutical agents for alleviating such diseases.

Career Highlights

Keiko Yamaguchi is currently associated with Eisai R&D Management Co., Ltd. Her work at this esteemed organization has allowed her to further her research and contribute to advancements in medical science.

Collaborations

Some of her notable coworkers include Toshio Imai and Kenzo Muramoto. Their collaborative efforts have played a crucial role in the development of innovative solutions in the field of immunology.

Conclusion

Keiko Yamaguchi's contributions to the detection of Th1 cells represent a significant advancement in medical research. Her innovative methods and collaborative spirit continue to pave the way for future discoveries in the field.